CSPC PHARMA News

Shiyao Group (1093.HK): Harvesting impacts fully absorb star products to maintain their potential, innovation and transformation will enter a period of intensive harvesting

第一上海Apr 10 00:00

Shi Pharmaceutical (1093.HK): Innovative drugs drive steady growth in proprietary pharmaceutical business revenue, and API prices are expected to stabilize

華興證券Mar 27 00:00

CSPC Group (1093.HK): Revenue is expected to resume double-digit growth in 2024

中泰國際Mar 25 00:00

CSPC Group (1093.HK): Performance is in line with expectations and is expected to grow by double digits in 2024

國泰君安Mar 22 19:31

CSPC Group (01093.HK): Steady growth in performance, innovation and internationalization have been realized one after another

廣發證券Mar 22 00:00

CSPC PHARMACEUTICAL(1093.HK):4Q RESULTS MISSED; OPTIMISTIC 2024 GUIDANCE OF DOUBLE-DIGIT GROWTH

中银国际Mar 21 16:52

Goldman Sachs: The target price for the “buy” rating of CSPC (01093) was raised to HK$9.73

Zhitong FinanceMar 21 11:06

CSPC Group (1093.HK): Stable annual results, driven by eight major innovation platforms

華泰證券Mar 21 10:11

CSPC Group (01093.HK): Steady performance, expected double-digit increase in revenue and profit in 2024

中金公司Mar 21 08:11

CSPC Group (1093.HK): 2023 is in line with expectations, maintaining the 2024 double-digit growth rate guidelines, and sales of new products are gradually improving

交銀國際Mar 20 00:00

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.41 From HK$8.98, Keeps at Buy

MT NewswiresMar 14 20:47

Nomura: Maintaining CSPC Group's (01093) “Buy” rating and raising the target price to HK$9.41

Zhitong FinanceMar 14 11:08

CSPC Group (1093.HK): New Novartis acquires key asset subsidiaries within the Group to further strengthen collaboration; maintain purchases

交銀國際Jan 25 00:00

CSPC Group (1093.HK): Innovative drug research and development is rapidly advancing, and performance is about to resume rapid growth

國元國際Dec 27, 2023 00:00

Bank Ratings丨Daiwa: Shengshi Pharmaceutical Group (1093.HK) has a target price of HK$7.6, maintaining an outperforming market rating

Gelonghui FinanceDec 4, 2023 13:49

Shiyao Pharmaceutical Group (1093.HK): Neural sector maintains high growth and new product release can be expected

國泰君安Dec 4, 2023 07:42

Shiyao Pharmaceutical Group (01093.HK): Integrated implementation of innovative assets in line with expectations in the 3rd quarter

中金公司Dec 1, 2023 20:16

Shiyao Pharmaceutical Group (1093.HK): 3Q23 performance is basically in line with expectations, revenue growth is expected to rebound to double digits in 2024

交銀國際Dec 1, 2023 17:02

Shiyao Pharmaceutical Group (1093.HK): Innovative drug pipelines enrich performance and steady growth

國元國際Nov 30, 2023 00:00

Shiyao Pharmaceutical Group (1093.HK): Bank of China Bank International's 2023 Medical Industry Enterprise Daily Report

交銀國際Nov 24, 2023 00:00